We also note that TMP195, a first-in-class highly selective class II HDAC inhibitor, has shown potent activity in breast cancer mouse model studies [70], making it an attractive candidate to test in JMML patients who display increased HDAC5 and HDAC9 activity. Here, HDAC9 is linked to juvenile myelomonocytic leukemia.